Blood cancers

Early promise with zanubrutinib in mantle cell lymphoma

Zanubrutinib is well tolerated and has demonstrated activity in patients with relapsed or refractory mantle cell lymphoma (MCL). A study, published in Blood Advances, reported the safety and efficacy of the BTK inhibitor in the subgroup of patients with R/R MCL enrolled in an ongoing study of zanubrutinib in various B-cell malignancies. The phase 1/2 ...

Already a member?

Login to keep reading.

© 2021 the limbic